

Closed (archived) studies

TELESTAR UK PI Martyn Caplin [NCRN502]	Abstract: Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial). Kulke et al, European Cancer Congress 2015; 37LBA (29/09/2015) Publication:
NETTER-1 UK PI Ashley Grossman [NCRN328]	Abstract: ¹⁷⁷ Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial. Strosberg, J et al. The European Cancer Congress 2015; abstr 6LBA (27/09/2015) Publication:
RADIANT-4 UK PI Juan Valle [NCRN333]	Abstract: Everolimus in advanced non-functional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study. Yao, J et al. European Cancer Congress 2015; abstr 5LBA Publication: Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> . 2016 Mar 5;387(10022):968-77.
BEZ235-Z2401 UK PI Juan Valle [NCRN379]	Abstract: Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET). Salazar et al <i>J Clin Oncol</i> (Meeting Abstracts) May 2015 vol. 33 no. 15_suppl 4102 Publication: Fazio N, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, Lahner H, DE Herder WW, Raderer M, Teulé A, Capdevila J, Libutti SK, Kulke MH, Shah M, Dey D, Turri S, Aimone P, Massacesi C, Verslype C. A phase II study of BEZ235 in patients with Everolimus-resistant, advanced pancreatic neuroendocrine tumours. <i>Anticancer Res</i> . 2016 Feb;36(2):713-9.
BEZ235-F2201 UK PI Nick Reed [NCRN 12919]	Abstract: Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET). Salazar et al <i>J Clin Oncol</i> (Meeting Abstracts) May 2015 vol. 33 no. 15_suppl 4102 Publication: Fazio N, Buzzoni R, Baudin E et al. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. <i>Anticancer Res</i> 2016; 36: 713-719.
COOPERATE-2 UK PI Juan Valle [NCRN239]	Abstract: Kulke MH, Ruszniewski P, Van Cutsem E, Valle JW, De Herder W, Pavel M, Degtyarev E, Lam DH, Salazar R, Borbath I, Fazio N, Lombard-Bohas C and Yao JC. A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors: COOPERATE-2 Trial. Presented at ENETS 2015 Publication:
